Pfizer De-Risks Renal Drug Development Via SFJ Pharma Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
In another sign of Big Pharma’s growing need to curb development cost and risk, Pfizer has engaged drug development company SFJ Pharmaceuticals to fund and supervise a Phase III trial of renal cancer candidate axitinib in Asia.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?